Chronic delayed-type hypersensitivity reaction as a means to treat alopecia areata

Clinical and Experimental Immunology

Volumn 135, Issue 3, 2004, Pages 398-408

  Zoller M ^a,b   Freyschmidt Paul, P ^c   Vitacolonna, M ^a   McElwee, K J ^c   Hummel, S ^a   Hoffmann, R ^c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF KARLSRUHE   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Adhesion molecules; Autoimmune disease; Delayed type hypersensitivity; Leucocyte recruitment

Indexed keywords

HERMES ANTIGEN; SQUARIC ACID DIBUTYL ESTER;

ALOPECIA AREATA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONTACT DERMATITIS; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG EFFECT; ECZEMA; EXTRAVASATION; LYMPH NODE; LYMPH NODE CELL; MONOCYTE; MOUSE; MOUSE STRAIN; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ALLERGENS; ALOPECIA AREATA; ANIMALS; AUTOIMMUNE DISEASES; CELLS, CULTURED; CYCLOBUTANES; HYPERSENSITIVITY, DELAYED; IMMUNOPHENOTYPING; IMMUNOTHERAPY; LEUKOCYTES; LYMPH NODES; MICE; MICE, INBRED C3H; SKIN; T-LYMPHOCYTE SUBSETS;

EID: 1542379749     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2003.02380.x     Document Type: Article

References (78)

1. Kalish RS, Johnson KL, Hordinsky MK. Alopecia areata. Autoreactive T cells are variably enriched in scalp lesions relative to peripheral blood. Arch Dermatol 1992; 128:1072-7.
2. Randall VA. Is alopecia areata an autoimmune disease? Lancet 2001; 358:1922-4.
3. McElwee KJ, Tobin DJ, Bystryn JC et al. Alopecia areata: an autoimmune disease? Exp Dermatol 1999; 8:371-9.
4. McElwee KJ, Boggess D, King LE, Sundberg JP. Experimental induction of alopecia areata-like hair loss in C3H/HeJ mice using full-thickness skin grafts. J Invest Dermatol 1998; 111:797-803.
5. Gilhar A, Ullmann Y, Berkutzki T et al. Autoimmune hair loss (alopecia areata) transferred by T lymphocytes to human scalp explants on SCID mice. J Clin Invest 1998; 101:62-7.
6. Carroll JM, McElwee KJE, King L et al. Gene array profiling and immunomodulation studies define a cell-mediated immune response underlying the pathogenesis of alopecia areata in a mouse model and humans. J Invest Dermatol 2002; 119:392-402.
7. Gilhar A, Landau M, Assy B et al. Melanocyte-associated T cell epitopes can function as autoantigens for transfer of alopecia areata to human scalp explants on Prkdc (scid) mice. J Invest Dermatol 2001; 117:1357-62.
8. Paus R, Slominski A, Czarnetzki BM. Is alopecia areata an autoimmune-response against melanogenesis-related proteins, exposed by abnormal MHC class I expression in the anagen hair bulb? Yale J Biol Med 1993; 66:541-54.
9. Zhang JG, Oliver RF. Immunohistological study of the development of the cellular infiltrate in the pelage follicles of the DEBR model for alopecia areata. Br J Dermatol 1994; 130:405-14.
10. Freyschmidt-Paul P, Sundberg JP, Happle R et al. Successful treatment of alopecia areata-like hair loss with the contact sensitizer squaric acid dibutylester (SADBE) in C3H/HeJ mice. J Invest Dermatol 1999; 113:61-8.
11. Christoph T, Muller-Rover S, Audring H et al. The human hair follicle immune system: cellular composition and immune privilege. Br J Dermatol 2000; 142:862-73.
12. MacDonald N, Wiseman MC, Shapiro J. Alopecia areata: topical immunotherapy - application and practical problems. J Cutan Med Surg 1999; 3:36-40.
13. Papadopoulos AJ, Schwartz RA, Janniger CK. Alopecia areata. Pathogenesis, diagnosis, and therapy. Am J Clin Dermatol 2000; 1:101-5.
14. Hoffmann R, Wenzel E, Huth A et al. Growth factor mRNA levels in alopecia areata before and after treatment with the contact allergen diphenylcyclopropenone. Acta Derm Venereol 1996; 76:17-20.
15. Happle R, Echternacht K. Induction of hair growth in alopecia areata with D. N. C. B. Lancet 1997; 2:1002-3.
16. Happle R, Kalveram KJ, Buchner U et al. Contact allergy as a therapeutic tool for alopecia areata: application of squaric acid dibutylester. Dermatologica 1980; 161:289-97.
17. Stricker RB, Goldberg B. Significance of cytokine patterns in alopecia areata before and after therapeutic allergic contact dermatitis. J Invest Dermatol 1996; 106:379-80.
18. Buckley DA, Du Vivier AW. The therapeutic use of topical contact sensitizers in benign dermatoses. Br J Dermatol 2001; 145:385-405.
19. Freyschmidt-Paul P, Hoffmann R, Levine E et al. Current and potential agents for the treatment of alopecia areata. Curr Pharm Des 2001; 7:213-30.
20. McHugh RS, Shevach EM. The role of suppressor T cells in regulation of immune responses. J Allergy Clin Immunol 2002; 110:693-702.
21. Horwitz DA, Gray JD, Zheng SG. The potential of human regulatory T cells generated ex vivo as a treatment for lupus and other chronic inflammatory diseases. Arthritis Res 2002; 4:241-6.
22. Chinen J, Shearer WT. Basic and clinical immunology. J Allergy Clin Immunol 2003; 111:813-8.
23. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003; 3:745-56.
24. O'Reilly LA, Strasser A. Apoptosis and autoimmune disease. Inflamm Res 1999; 48:5-21.
25. Mountz JD, Zhou T, Su X, Wu J, Cheng J. The role of programmed cell death as an emerging new concept for the pathogenesis of autoimmune diseases. Clin Immunol Immunopathol 1996; 80:2-14.
26. Zöller M, McElwee KJ, Engel P, Hoffmann R. Transient CD44 variant isoform expression and reduction in CD4(+)/CD25(+) regulatory T cells in C3H/ HeJ mice with alopecia areata. J Invest Dermatol 2002; 118:983-92.
27. Rösel M, Seiter S, Zöller M. CD44v10 expression in the mouse and functional activity in delayed type hypersensitivity. J Cell Physiol 1997; 171:305-17.
28. Freyschmidt-Paul P, Seiter S, Zöller M et al. Treatment with an anti-CD44v10-specific antibody inhibits the onset of alopecia areata in C3H/HeJ mice. J Invest Dermatol 2000; 115:653-7.
29. Wagner SN, Wagner C, Reinhold U et al. Predominant expression of CD44 splice variant v10 in malignant and reactive human skin lymphocytes. J Invest Dermatol 1998; 111:464-71.
30. Zöller M. CD44v10 in hematopoiesis and stem cell mobilization. Leuk Lymph 2000; 38:463-80.
31. Katagiri YU, Sleeman J, Fujii H et al. CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res 1999; 59:219-26.
32. Ashkar S, Weber GF, Panoutsakopoulou V et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000; 287:860-4.
33. Denhardt DT, Noda M, O'Regan AW et al. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001; 107:1055-61.
34. Xuan JW, Hota C, Shigeyama Y et al. Site-directed mutagenesis of the arginine-glycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration functions. J Cell Biochem 1995; 57:680-90.
35. Nau GJ, Guilfoile P, Chupp GL et al. A chemoattractant cytokine associated with granulomas in tuberculosis and silicosis. Proc Natl Acad Sci USA 1997; 94:6414-9.
36. Weber GF, Zawaideh S, Hikita S et al. Phosphorylation-dependent interaction of osteopontin with its receptors regulates macrophage migration and activation. J Leukoc Biol 2002; 72:752-61.
37. Grimme HU, Termeer CC, Bennett KL et al. Colocalization of basic fibroblast growth factor and CD44 isoforms containing the variably spliced exon 3 (CD44v3) in normal skin and in epidermal skin cancers. Br J Dermatol 1999; 141:824-32.
38. Bennett KL, Jackson DG, Simon JC et al. CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor. J Cell Biol 1995; 128:687-98.
39. Tumova S, Woods A, Couchman JR. Heparan sulfate proteoglycans on the cell surface: versatile coordinators of cellular functions. Int J Biochem Cell Biol 2000; 32:269-88.
40. Seiter S, Engel P, Föhr N, Zöller M. Mitigation of delayed-type hypersensitivity reactions by a CD44 variant isoform v3-specific antibody: blockade of leukocyte egress. J Invest Dermatol 1999; 113:11-21.
41. Seiter S, Schadendorf D, Tilgen W, Zöller M. CD44 variant isoform expression in a variety of skin-associated autoimmune diseases. Clin Immunol Immunopathol 1998; 89:79-93.
42. Kuniyasu H, Oue N, Tsutsumi M et al. Heparan sulfate enhances invasion by human colon carcinoma cell lines through expression of CD44 variant exon 3. Clin Cancer Res 2001; 7:4067-72.
43. Weiss JM, Renkl AC, Maier CS et al. Osteopontin is involved in the initiation of cutaneous contact hypersensitivity by inducing Langerhans and dendritic cell migration to lymph nodes. J Exp Med 2001; 194:1219-29.
44. Cotellessa C, Peris K, Caracciolo E et al. The use of topical diphenylcyclopropenone for the treatment of extensive alopecia areata. J Am Acad Dermatol 2001; 44:73-6.
45. Wysocki LJ, Sato VL. 'Panning' for lymphocytes: a method for cell selection. Proc Natl Acad Sci USA 1978; 75:2844-8.
46. Peret C, Wiesner-Menzel L, Happle R. Immunohistochemical analysis of T-cell subsets in the peribulbar and intrabulbar infiltrates of alopecia areata. Acta Derm Venerol 1984; 64:26-30.
47. Ghersetich I, Campanile G, Lotti T. Alopecia areata: immunohistochemistry and ultrastructure of infiltrate and identification of adhesion molecule receptors. Int J Dermatol 1996; 35:28-33.
48. Ptak W, Herzog WR, Askenase PW. Delayed-type hypersensitivity initiation by early-acting cells that are antigen mismatched or MHC incompatible with late-acting, delayed-type hypersensitivity effector T cells. J Immunol 1991; 146:469-75.
49. Gibbs JH, Grange JM, Beck JS et al. Early delayed hypersensitivity responses in tuberculin skin tests after heavy occupational exposure to tuberculosis. J Clin Pathol 1991; 44:919-23.
50. Sjögren F, Anderson C. The spectrum of inflammatory cell response to dimethyl sulfoxide. Contact Dermatitis 2000; 42:216-21.
51. Buchanan KL, Murphy JW. Kinetics of cellular infiltration and cytokine production during the efferent phase of a delayed-type hypersensitivity reaction. Immunology 1997; 90:189-97.
52. + immunoregulatory T cells that control autoimmune diabetes. Immunity 2000; 12:431-40.
53. McElwee KJ, Silva K, Boggess D et al. Alopecia areata in C3H/HeJ mice involves leukocyte mediated sheath disruption in advance of overt hair loss. Vet Pathol, in press.
54. Takahashi T, Tagami T, Yamazaki S et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000; 192:303-10.
55. + suppressor T cells. J Exp Med 2001; 193:41-5.
56. McElwee KJ, Hoffmann R, Freyschmidt-Paul P et al. Resistance to alopecia areata in C3H/HeJ mice is associated with increased expression of regulatory cytokines and a failure to recruit CD4(+) and CD8(+) cells. J Invest Dermatol 2002; 119:1426-33.
57. Teraki Y, Imanishi K, Shiohara T. Cytokines in alopecia areata: contrasting cytokine profiles in localized form and extensive form (alopecia universalis). Acta Derm Venereol 1996; 76:421-3.
58. DeGrendele HC, Estess P, Siegelman MH. Requirement for CD44 in activated T cell extravasation into an inflammatory site. Science 1997; 278:672-5.
59. Estess P, Nandi A, Mohamadzadeh M, Siegelman MH. Interleukin 15 induces endothelial hyaluronan expression in vitro and promotes activated T cell extravasation through a CD44-dependent pathway in vivo. J Exp Med 1999; 190:9-19.
60. Jackson DG, Bell JI, Dickinson R et al. Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon. J Cell Biol 1995; 128:673-85.
61. Boring L, Gosling J, Chensue SW et al. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest 1997; 100:2552-61.
62. Pichler WJ, Yawalkar N, Britschgi M et al. Cellular and molecular pathophysiology of cutaneous drug reactions. Am J Clin Dermatol 2002; 3:229-38.
63. Ohmen JD, Hanifin JM, Nickoloff BJ et al. Overexpression of IL10 in atopic dermatitis. Contrasting cytokine patterns with delayed-type hypersensitivity reactions. J Immunol 1995; 154:1956-63.
64. Lu B, Rutledge BJ, Gu L et al. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J Exp Med 1998; 187:601-8.
65. + T helper cells. J Exp Med 2002; 196:255-60.
66. + regulatory contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells. J Exp Med 2002; 196:247-53.
67. Tanaka Y, Adams DH, Hubscher S et al. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1 beta. Nature 1993; 361:79-82.
68. Witt DP, Lander AD. Differential binding of chemokines to glycosaminoglycan subpopulations. Curr Biol 1994; 4:394-400.
69. Gallo RL. Proteoglycans and cutaneous vascular defense and repair. J Invest Dermatol Symp Proc 2000; 5:55-60.
70. Yu X, Barnhill RL, Graves DT. Expression of monocyte chemoattractant protein-1 in delayed type hypersensitivity reactions in the skin. Lab Invest 1994; 71:226-35.
71. Santamaria-Babi LF, Moser B, Perez-Soler MT et al. The interleukin-8 receptor B and CXC chemokines can mediate transendothelial migration of human skin homingT cells. Eur J Immunol 1996; 26:2056-61.
72. Santamaria-Babi LF, Perez-Soler MT, Hauser C, Blaser K. Skin-homing T cells in human cutaneous allergic inflammation. Immunol Res 1995; 14:317-24.
73. Egan PJ, Kimpton W, Seow HF et al. Inflammation-induced changes in the phenotype and cytokine profile of cells migrating through skin and afferent lymph. Immunology 1996; 89:539-46.
74. Rand ML, Warren JS, Mansour MK et al. Inhibition of T cell recruitment and cutaneous delayed-type hypersensitivity-induced inflammation with antibodies to monocyte chemoattractant protein-1. Am J Pathol 1996; 148:855-64.
75. Sebastiani S, De Albanesi C, PO et al. The role of chemokines in allergic contact dermatitis. Arch Dermatol Res 2002; 293:552-9.
76. Lin YH, Yang-Yen HF. The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem 2001; 276:46024-30.
77. Kimura R, Hu H, Stein-Streilein J. Delayed-type hypersensitivity responses regulate collagen deposition in the lung. Immunology 1992; 77:550-5.
78. Wangoo A, Cook HT, Taylor GM, Shaw RJ. Enhanced expression of type 1 procollagen and transforming growth factor-beta in tuberculin induced delayed type hypersensitivity. J Clin Pathol 1995; 48:339-45.